美国的喘三重治疗的现实世界用户
Nadia N Hansel, Carl B Abbott, Carlyne M Averell1
1GSK, 5 Moore Dr, Research Triangle Park, NC 27709.
The American journal of managed care
|February 21, 2024
概括
对于持久性喘患者来说,三重疗法是推的选择. 现实数据显示,这些患者在开始三重疗法之前往往有很高的疾病负担,这表明潜在的控制不足.
科学领域:
- 肺部病理学 肺部病理学
- 现实世界的证据研究研究.
- 药物治疗 药物治疗
背景情况:
- 喘管理指南建议在吸入性皮质类固醇/长效β2agonist (ICS/LABA) 治疗的症状患者中添加长效肌抗体 (LAMA).
- 有限的现实世界数据存在于开始三重治疗的患者的特征和治疗模式.
研究的目的:
- 描述新使用单或多吸入器三重疗法 (SITT/MITT) 的新用户的人口统计和临床特征.
- 分析喘患者在开始三重治疗之前的治疗模式.
主要方法:
- 使用医疗和药房索赔数据 (IQVIA PharMetrics Plus) 的回顾性队列研究.
- 包括患有喘的成年人 (有或没有COPD) 启动SITT (流酸/乌克利迪尼/维兰特罗尔) 或MITT.
- 在三重治疗开始前12个月分析了基线人口统计数据,临床特征和治疗模式.
主要成果:
- 包括12,395名患者.
- 在SITT发起者 (n=1301) 中,平均年龄为49.0岁,59.3%是女性.
- 在启动前,81.5%使用控制疗法,94.7%使用救援药物,42.0%患有≥1次喘恶化 (年率0.96).
结论:
- 三重治疗通常是在其他喘控制药物后开始的.
- 高基线疾病负担 (救援药物使用,恶化) 表明在三重治疗开始前喘控制不足.
相关概念视频
Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Asthma-III: Symptoms and Complications
2.5K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
Classification of Asthma
2.5K
Asthma-IV: Nursing Management
3.1K
The nursing management of asthma is a comprehensive approach that relies heavily on the expertise and dedication of healthcare professionals. It involves thorough assessment, accurate diagnosis, strategic planning, effective implementation, and diligent evaluation. By meticulously following this step-by-step process, healthcare professionals play a crucial role in providing the best possible care and treatment for patients with asthma, enhancing their overall health and well-being.
First, in...
First, in...
3.1K
Asthma: Pathogenesis and Management
398
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
398
Antiasthma Drugs: Leukotriene Modifiers
298
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
298
Asthma-II: Pathophysiology and Classification
2.7K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.7K


